Nausea News and Research

RSS

Nausea is the sensation of unease and discomfort in the upper stomach and head with an urge to vomit. An attack of nausea is known as a qualm.

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration approved Afinitor tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin in patients with unresectable, locally advanced or metastatic disease.

6 May 2011

Pfizer’s Revatio receives European Commission approval for pediatric treatment of pulmonary arterial hypertension

Pfizer Inc. announced that Revatio (sildenafil citrate) has been approved by the European Commission for the treatment of pediatric patients aged 1 to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.

5 May 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2011.

5 May 2011

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Two studies to be presented this week address the often-overlooked costs associated with atrial fibrillation, the most common form of cardiac arrhythmia.

5 May 2011

Childhood cancer survivors may face high risk of late GI complications after therapy

Patients who received therapy for cancer during childhood have an increased risk of developing gastrointestinal complications later in life, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute.

5 May 2011

South Australian man succumbs to Murray Valley Encephalitis

A 27-year-old South Australian Riverland man has succumbed to Murray Valley Encephalitis (MVE) – a viral disease that is carried by mosquitoes. According to SA Health's chief medical officer Paddy Phillips, the man had been receiving hospital care for MVE since March.

3 May 2011

Ipsen first quarter sales increase 6.1% to €285.8 million

Ipsen reported today its sales for the first quarter 2011.

3 May 2011

Affinium announces AFN-1252 Phase I study results in staphylococcal infections

Affinium Pharmaceuticals announced today the results of a new multiple ascending dose Phase I study of its novel, selective-spectrum, anti-staphylococcal agent, AFN-1252 in a novel oral formulation.

3 May 2011

Scientists discover new gene underlying angle-closure glaucoma

Jackson Laboratory researchers and their collaborators have reported their discovery of a gene implicated in an acute and severe form of glaucoma known as angle-closure glaucoma.

3 May 2011

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

AstraZeneca announced today that the U.S. Food and Drug Administration has approved the use of NEXIUM I.V. for Injection for children ages greater than 1 month old for the short-term treatment of gastroesophageal reflux disease with erosive esophagitis when oral therapy is not possible or appropriate.

3 May 2011

Watson launches Generess Fe low-dose oral contraceptives in the U.S.

Watson Pharmaceuticals, Inc., today announced the U.S. commercial launch of Generess Fe 0.8 mg/25 mcg, a new low-dose oral contraceptive option that's highly effective at preventing pregnancy and proven to provide users with short, lighter, predictable periods.

2 May 2011

Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Eli Lilly Canada announced today that Health Canada has approved Cymbalta for the management of chronic low back pain.

30 Apr 2011

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, received approval from the U.S. Food and Drug Administration on April 29, 2011, for the use of FUSILEV in combination with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer.

30 Apr 2011

Antiviral Drugs Advisory Committee recommends FDA to approve telaprevir for hepatitis C

Vertex Pharmaceuticals Incorporated announced that the Antiviral Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously to recommend FDA approval of telaprevir for people with genotype 1 chronic hepatitis C.

29 Apr 2011

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

Affymax, Inc. and Takeda Pharmaceutical Company Limited, today announced results of additional analyses from two Phase 3 studies of the investigational agent, peginesatide in chronic renal failure patients on dialysis with anemia.

29 Apr 2011

More women using ‘morning after’ pill

Figures have revealed that the rate of women using emergency contraception in 2006-08 more than doubled, compared with the rate in the previous four to six years, before the pills were approved for use without a prescription. This comes from a study from the Guttmacher Institute.

29 Apr 2011

Curis reports first quarter net loss of $6.8 million

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today reported its financial results for the first quarter ended March 31, 2011.

28 Apr 2011

Positive results from Shire's Vyvanse clinical trial in schizophrenia

Shire plc, the global specialty biopharmaceutical company, today announced positive results from a signal-finding study of Vyvanse(R) Capsules assessing its effect in a prospective examination of adults with negative symptom predominant schizophrenia.

28 Apr 2011

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Alkermes, Inc. today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo.

28 Apr 2011

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.

27 Apr 2011

Nausea News and Research

Further Reading

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

Pfizer’s Revatio receives European Commission approval for pediatric treatment of pulmonary arterial hypertension

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Childhood cancer survivors may face high risk of late GI complications after therapy

South Australian man succumbs to Murray Valley Encephalitis

Ipsen first quarter sales increase 6.1% to €285.8 million

Affinium announces AFN-1252 Phase I study results in staphylococcal infections

Scientists discover new gene underlying angle-closure glaucoma

AstraZeneca receives FDA approval for NEXIUM I.V. to treat GERD with erosive esophagitis

Watson launches Generess Fe low-dose oral contraceptives in the U.S.

Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Spectrum receives FDA approval for FUSILEV to treat colorectal cancer

Antiviral Drugs Advisory Committee recommends FDA to approve telaprevir for hepatitis C

Takeda, Affymax announce additional peginesatide Phase 3 study results in dialysis patients

More women using ‘morning after’ pill

Curis reports first quarter net loss of $6.8 million

Positive results from Shire's Vyvanse clinical trial in schizophrenia

The Lancet publishes phase 3 clinical study data on VIVITROL for treatment of opioid dependence

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News